ASP Isotopes hosts inaugural Capital Markets Day, outlines production milestones and $300M EBITDA 2031 target

ASP Isotopes targets $300 million EBITDA by 2031 following its inaugural Capital Markets Day, driven by liquid helium, radiopharmacy, and stable isotope commercialization. The company also announced plans for separate public listings of its subsidiary ventures.